脑力超过了2025年对收入的预期,实现了强劲增长,并扩大了治疗核准和供资范围。 Brainsway exceeded earnings expectations in 2025, posted strong growth, and expanded its treatment approvals and funding.

脑力报告了强劲的Q4和2025年全年成果,收入为1 455万美元,EPS收入为14美元,超过估计数。 Brainsway reported strong Q4 and full-year 2025 results, with revenue of $14.55 million and EPS of $0.14, exceeding estimates. 该公司全年收入增长27%,实现了第10个直接盈利的季度,并将其安装基础扩大到约1 700个深TMS系统。 The company saw 27% year-over-year revenue growth, achieved its 10th straight profitable quarter, and expanded its installed base to about 1,700 Deep TMS systems. 它为青少年抑郁症患者争取到了FDA的标签扩展，获得了支付方的保险覆盖，并获得了加速治疗方案的批准。 It secured FDA label expansion for adolescents with depression, gained payer coverage advances, and received clearance for an accelerated treatment protocol. Brainsway还宣布了一项由NIH资助的250万美元酒精使用障碍试验，并计划提交FDA关于PTSD的申请。 Brainsway also announced a $2.5 million NIH-funded trial for alcohol use disorder and plans an FDA submission for PTSD. 它预测2026年的收入为6,600万至6,800万美元,经调整的EBITDA为1,200万至1,400万美元。 It projected 2026 revenue of $66–68 million and adjusted EBITDA of $12–14 million.